Maryland is currently home to 2687 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Robot Aided Rehabilitation - Multi-joint Evaluations
NCT02359812
Recruiting
Sensory and motor impairments following stroke can lead to substantial disability involving the arm and hand. The investigator hypothesized that excessive local and cross-coupled stiffness, diminished individuation and proprioceptive acuity will be present among multiple degree of freedom in the upper limb. The stiffness and spasticity will increase with time post-stroke. The objective of this study is to quantify the progression throughout the arm and hand during recovery from stroke. The inves... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/02/2024
Locations: University of Maryland, Baltimore, Baltimore, Maryland
Conditions: Stroke
Register for Updates
Robot Aided Rehabilitation - Intervention
NCT02359253
Recruiting
Sensorimotor impairments following stroke often involve complex pathological changes across multiple joints and multiple degrees of freedom of the arm and hand, thereby rendering them difficult to diagnose and treat. The objective of this study is to evaluate multi-joint neuromechanical impairments in the arm and hand, then conduct impairment-specific treatment, and determine the effects of arm versus hand training and the effects of passive stretching before active movement training.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/02/2024
Locations: University of Maryland, Baltimore, Baltimore, Maryland
Conditions: Stroke
Register for Updates
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
NCT05312671
Recruiting
This is a single arm, Phase II trial involving the use of atezolizumab plus platinum and etoposide for patients with locally advanced urothelial cancer. The primary goal of this trial is to assess the pathologic complete response rate at cystectomy in patients after being treated with a combination therapy of atezolizumab, platinum, and etoposide.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2024
Locations: Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Small Cell Neuroendocrine Carcinoma of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder
Register for Updates
Telehealth Parent-Implemented Intervention for Young Children With Autism Spectrum Disorder (ASD)
NCT05176808
Recruiting
The primary objective of this research study is to improve outcomes involving core social-communication symptoms for young children with ASD by increasing access to clinically validated early behavioral intervention through a telehealth parent coaching model. The investigators will test the hypothesis that telehealth-delivered Naturalistic Developmental Behavioral Intervention parent coaching (TC) is non-inferior to in-person coaching (IPC) for the treatment of core social-communication symptoms... Read More
Gender:
ALL
Ages:
Between 18 months and 33 months
Trial Updated:
07/01/2024
Locations: Kennedy Krieger Institute, Baltimore, Maryland
Conditions: Autism Spectrum Disorder
Register for Updates
Natural History Study of Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation (LBSL)
NCT03624374
Recruiting
In this study, we will conduct retrospective chart and imaging reviews and prospective longitudinal virtual assessments of individuals with LBSL.
Gender:
ALL
Ages:
All
Trial Updated:
07/01/2024
Locations: Hugo Moser Center for Leukodystrophies, Baltimore, Maryland
Conditions: Leukoencephalopathies, LBSL, Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, White Matter Disease, Ataxia, Cerebellar, Genetic Disease
Register for Updates
Investigation on the Cortical Communication (CortiCom) System
NCT03567213
Recruiting
The CortiCom system consists of 510(k)-cleared components: platinum PMT subdural cortical electrode grids, a Blackrock Microsystems patient pedestal, and an external NeuroPort Neural Signal Processor. Up to two grids will be implanted in the brain, for a total channel count of up to 128 channels, for six months. In each participant, the grid(s) will be implanted over areas of cortex that encode speech and upper extremity movement.
Gender:
ALL
Ages:
Between 22 years and 70 years
Trial Updated:
07/01/2024
Locations: Johns Hopkins Medicine, Baltimore, Maryland
Conditions: Tetraplegia, Locked-in Syndrome, Brainstem Stroke, Amyotrophic Lateral Sclerosis
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Anne Arundel Medical Center, Annapolis, Maryland
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
NCT06257693
Recruiting
The study is to assess whether the Enolen is safe and delivers anti-androgen medication locally in patients that are planning for radical prostatectomy.
Gender:
MALE
Ages:
21 years and above
Trial Updated:
06/26/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Prostate Adenocarcinoma
Register for Updates
Evaluation of an Investigational Wearable Vital Signs Monitoring Device in Healthy Infants
NCT05910320
Recruiting
The primary objective of this study is to evaluate the feasibility of the use of an investigational wearable vital sign monitoring device in infants.
Gender:
ALL
Ages:
Between 1 day and 1 year
Trial Updated:
06/26/2024
Locations: Johns Hopkins Children's Center, Baltimore, Maryland
Conditions: Congenital Heart Disease in Children
Register for Updates
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
NCT03053193
Recruiting
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Luminis Health Center for Cancer & Blood Disorders, Annapolis, Maryland
Conditions: Breast Cancer
Register for Updates
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (AAVIATE)
NCT04514653
Recruiting
RGX-314 is being developed as a potential novel one-time gene therapy treatment for the treatment of neovascular (wet) age related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-VEGF therapies have significantly changed the landscape for tre... Read More
Gender:
ALL
Ages:
Between 50 years and 89 years
Trial Updated:
06/25/2024
Locations: Baltimore Location, Baltimore, Maryland
Conditions: Neovascular Age-Related Macular Degeneration (nAMD)
Register for Updates
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
NCT05230537
Recruiting
The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/24/2024
Locations: Retina Care Center Research, Baltimore, Maryland
Conditions: Age-Related Macular Degeneration
Register for Updates